Related Experiment Video
Updated: Apr 2, 2026
13:34
Assessing the Development of Murine Plasmacytoid Dendritic Cells in Peyer's Patches Using Adoptive Transfer of Hematopoietic Progenitors
Published on: March 17, 2014
11.6K
Differential Plasma-cell evolution is linked with Dermatophagoides pteronyssinus immunotherapy response
Tahia D Fernández1, Enrique Gómez1, Inmaculada Doña2
1Research Laboratory-Allergy Unit, IBIMA-Regional University Hospital of Malaga, UMA, Malaga, Spain.
Scientific Reports
|September 30, 2015
Summary
Identifying specific B-cell and plasma-cell changes during allergen immunotherapy (AIT) can predict treatment success. Memory B-cells before treatment and IgG4 levels early in AIT may indicate clinical response in allergic rhinitis patients.
Area of Science:
- Immunology
- Allergy Research
Background:
- Allergic rhinitis affects many globally, with immunotherapy (AIT) being a common treatment.
- Up to 30% of patients do not respond to AIT, necessitating research into predictive biomarkers.
- Previous AIT research focused on T-cells and humoral responses, leaving B-cell roles less understood.
Purpose of the Study:
- To investigate the impact of AIT on various B-cell and plasma-cell subsets.
- To determine if changes in these cell populations correlate with clinical outcomes in AIT.
Main Methods:
- Analysis of B-cell and plasma-cell subpopulations in patients undergoing AIT.
- Correlation of cellular changes with clinical response to allergen immunotherapy.
Main Results:
- No significant changes observed in overall B-cell subpopulations.
- Responder patients exhibited higher memory B-cell levels pre-treatment.
- Significant alterations noted in plasma-cell subsets, particularly circulating inflammatory plasma-cells.
- An early increase in specific IgG4 and IgG4-secreting cells was detected in responders.
Conclusions:
- Memory B-cell levels pre-AIT may predict treatment response.
- Quantifying IgG4 and IgG4-secreting cells early in AIT could serve as response markers.
- These cellular markers may help personalize allergic rhinitis immunotherapy.
